(Boursier.com) – Johnson & johnson, the U.S. pharmaceutical and medical giant, announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States, showing that a single dose of its vaccine resulted in lasting protection for up to at six months against Covid-19 infections, hospitalizations and intensive care unit admissions. The study was sponsored by the Janssen Pharmaceutical Companies (Johnson & Johnson) and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of Pharmacoepidemiology, Department of Medicine at Brigham & Women’s Hospital and Harvard Medical School.
“We continue to make significant efforts to study the sustainability of the protection offered by the Johnson & Johnson vaccine amid the ever-evolving Covid-19 pandemic,” said Mathai Mammen, MD, Ph.D., vice Executive Chairman, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson. “Although these data are changing rapidly, we are seeing an efficacy of the vaccine against Covid-19 hospitalizations of about 80% from a single injection of the Johnson & Johnson vaccine, and this level of protection remains stable throughout. of the period studied so far – up to six months. The robust and sustained durability of our Covid-19 vaccine reflects its unique underlying immunology. We have previously reported that our vaccine induces a strong antibody response as well as a particularly strong increase in T lymphocytes which is consistent with the variants, including Omicron “.
The new study published on medRxiv extensively examined the durability profiles of the three vaccines licensed or approved in the United States using the same methodology for three outcomes: Covid-19 infections, hospitalizations, and intensive care admissions.
The study showed that the effectiveness of the Johnson & Johnson vaccine against infections and hospitalizations remained sustainable. The mRNA vaccines (two doses) have shown decreasing efficacy for hospitalizations and infections, notes J&J. All three vaccines have shown no evidence of decreased protection against Covid-19-related ICU admissions at any time, showing long-lasting strong protection against extremely serious illness. The study was not designed to compare the durability of vaccines.
© 2022 Boursier.com